Orthotopic Transcatheter Tricuspid Valve Replacement After Heterotopic Caval Valve Failure Authors: Matteo Biroli, Cong Lu, Cristina Ferrari, Fabio Fazzari, Antonio Mangieri, Federico De Marco Published: 2026 ABSTRACT BackgroundHeterotopic caval valve implantation has emerged as a compassionate transcatheter option for patients with severe tricuspid regurgitation (TR) deemed unsuitable for edge-to-edge repair. However, long-term durability and management of device failure remain poorly defined.Case SummaryWe report the case of a 70-year-old woman with prior heterotopic TricValve implantation because of massive TR, who presented with recurrent right-sided heart failure secondary to inferior vena cava prosthetic dysfunction. Multimodality imaging revealed the known significant TR and severe degeneration of the heterotopic valve at the inferior vena cava position, and confirmed anatomical suitability for orthotopic transcatheter tricuspid valve replacement (TTVR). The patient subsequently underwent successful Evoque TTVR, achieving complete TR abolition and TricValve unloading.Discussion and Take-Home MessagesThis case highlights the versatility of TTVR as a comprehensive solution for clinically significant TR. Guided by advanced multimodality imaging, Evoque TTVR effectively provided definitive TR correction without any device interaction in a complex anatomical setting. Visual SummaryThe Upper Panels Summarize the Patient’s Clinical History and Presentation After Previous TricValve Implantation for Severe Tricuspid RegurgitationThe central panels illustrate the evidence of TricValve degeneration, with dysfunction of the inferior caval valve prosthesis characterized by loss of leaflet coaptation, cusp prolapse, and recurrent regurgitant flow toward the inferior vena cava. The lower panels depict the subsequent transcatheter treatment strategy with Evoque transcatheter tricuspid valve replacement. MVR = mitral valve replacement; TEER = transcatheter edge-to-edge repair. The Upper Panels Summarize the Patient’s Clinical History and Presentation After Previous TricValve Implantation for Severe Tricuspid Regurgitation The central panels illustrate the evidence of TricValve degeneration, with dysfunction of the inferior caval valve prosthesis characterized by loss of leaflet coaptation, cusp prolapse, and recurrent regurgitant flow toward the inferior vena cava. The lower panels depict the subsequent transcatheter treatment strategy with Evoque transcatheter tricuspid valve replacement. MVR = mitral valve replacement; TEER = transcatheter edge-to-edge repair. History of Presentation A 70-year-old woman was referred to our hospital because of progressively worsening dyspnea. On physical examination, mild bilateral lower-limb edema was evident, along with a small amount of ascites. These findings prompted a comprehensive diagnostic workup to define the underlying etiology and guide further therapeutic management.Take-Home Messages•Heterotopic caval valve implantation may fail over time and does not treat the native tricuspid valve pathology.•Transcatheter tricuspid valve replacement with the Evoque platform can be safely performed after failed heterotopic caval valve implantation, providing definitive tricuspid regurgitation treatment when prior caval therapy becomes ineffective. Take-Home Messages •Heterotopic caval valve implantation may fail over time and does not treat the native tricuspid valve pathology.•Transcatheter tricuspid valve replacement with the Evoque platform can be safely performed after failed heterotopic caval valve implantation, providing definitive tricuspid regurgitation treatment when prior caval therapy becomes ineffective. •Heterotopic caval valve implantation may fail over time and does not treat the native tricuspid valve pathology. Heterotopic caval valve implantation may fail over time and does not treat the native tricuspid valve pathology. •Transcatheter tricuspid valve replacement with the Evoque platform can be safely performed after failed heterotopic caval valve implantation, providing definitive tricuspid regurgitation treatment when prior caval therapy becomes ineffective. Transcatheter tricuspid valve replacement with the Evoque platform can be safely performed after failed heterotopic caval valve implantation, providing definitive tricuspid regurgitation treatment when prior caval therapy becomes ineffective. Past Medical History The patient’s medical history was notable for rheumatic valvular heart disease, treated with mechanical mitral valve (MV) replacement in 2003 and massive tricuspid regurgitation (TR). In March 2022, before CE mark approval of any transcatheter tricuspid valve replacement (TTVR) device, she underwent heterotopic transcatheter valve implantation (TricValve—Innova HTS) at another institution because of worsening symptoms. She was deemed unsuitable for transcatheter edge-to-edge repair because of a large coaptation gap and restricted leaflet motion. Approximately 1 year after the procedure, she developed recurrent progressive dyspnea. Relevant comorbidities included chronic hepatitis B. Differential Diagnosis The differential diagnosis for the patient’s signs and symptoms included:1.Structural dysfunction or malposition of the heterotopic caval valves, resulting in ineffective venous decongestion.2.Progressive right ventricle (RV) dysfunction, limiting the hemodynamic benefit of caval valves.3.Left-sided valvular or prosthetic dysfunction.4.Noncardiac contributors to volume overload such as renal or hepatic dysfunction. 1.Structural dysfunction or malposition of the heterotopic caval valves, resulting in ineffective venous decongestion. Structural dysfunction or malposition of the heterotopic caval valves, resulting in ineffective venous decongestion. 2.Progressive right ventricle (RV) dysfunction, limiting the hemodynamic benefit of caval valves. Progressive right ventricle (RV) dysfunction, limiting the hemodynamic benefit of caval valves. 3.Left-sided valvular or prosthetic dysfunction. Left-sided valvular or prosthetic dysfunction. 4.Noncardiac contributors to volume overload such as renal or hepatic dysfunction. Noncardiac contributors to volume overload such as renal or hepatic dysfunction. Investigations Laboratory testing showed a normal complete blood count. Renal function was preserved (creatinine = 0.92 mg/dL), despite mildly increased blood urea nitrogen (64 mg/dL). Electrolytes and liver function tests were within normal limits. Transthoracic echocardiography and transesophageal echocardiography (TEE) demonstrated the known torrential central TR (Figures 1A and 1B, Video 1), driven by severely fibrotic, thickened, and retracted tricuspid leaflets with marked hypomobility, particularly of the septal leaflet, resulting in a large central coaptation gap (up to 14-15 mm) and severe annular dilation (Figures 1C and 1D, Video 2). Right-sided chamber remodeling and dilation were evident, with RV systolic function at the lower limit of normal values.Figure 1TEE Assessment of Native Tricuspid Valve and Degenerated TricValveColor Doppler transesophageal echocardiography (TEE) demonstrating torrential central tricuspid regurgitation (A and B). Large central coaptation gap measuring up to 14 mm (C) and evidence of tricuspid annular dilation (D). Bicaval TEE views of the previously implanted TricValve prosthesis at the inferior vena cava. White arrow indicates the prosthetic cusp degeneration and prolapse (E), associated with severe prosthetic regurgitation (F) on color Doppler imaging. LA = left atrium; PAZ = ; RA = right atrium; RV = right ventricle; S = septal; SVC = superior vena cava. TEE Assessment of Native Tricuspid Valve and Degenerated TricValve Color Doppler transesophageal echocardiography (TEE) demonstrating torrential central tricuspid regurgitation (A and B). Large central coaptation gap measuring up to 14 mm (C) and evidence of tricuspid annular dilation (D). Bicaval TEE views of the previously implanted TricValve prosthesis at the inferior vena cava. White arrow indicates the prosthetic cusp degeneration and prolapse (E), associated with severe prosthetic regurgitation (F) on color Doppler imaging. LA = left atrium; PAZ = ; RA = right atrium; RV = right ventricle; S = septal; SVC = superior vena cava. The previously implanted heterotopic caval valve showed severe degeneration and regurgitation of the inferior vena cava (IVC) prosthesis, likely related to prosthetic cusp prolapse (Figures 1E and 1F, Video 3). The mechanical MV was normally positioned and functioning, and the aortic valve showed normal gradients with mild central regurgitation. Cardiac computed tomography (CT) confirmed adequate expansion of the IVC prosthesis without evidence of device migration or venous obstruction. Management Considering the patient’s high surgical risk, the Heart Team opted for a percutaneous treatment approach. Considering the large tricuspid coaptation gap, the patient was confirmed to be ineligible for transcatheter edge-to-edge repair. On the basis of the integrated clinical and multimodality imaging assessment, the patient was deemed anatomically and clinically suitable for TTVR with the Evoque platform (Edwards Lifesciences). CT highlighted that annular and RV anatomy were compatible with a 48-mm Evoque valve with annulus oversizing between 7.6% and 10.1% and basal RV oversizing between −8% and 8.9% in diastole and systole, respectively (Figures 2A to 2D); the previously implanted IVC TricValve prosthesis extended 18.7 mm into the right atrium (RA) (Figures 2E and 2F). Although anatomical feasibility for TTVR was confirmed, the presence of a prior TricValve system raised relevant procedural concerns, particularly regarding device interaction and spatial constraints within the RA.Figure 2Preprocedural Computed Tomography Planning for Transcatheter Tricuspid Valve ReplacementComputed tomography reconstruction of the tricuspid annulus in diastole (A) and systole (B), demonstrating annular dimensions, perimeter, and area measurements used for device sizing. Computed tomography-based assessment of right ventricle septo-lateral dimensions in diastole (C) and systole (D). Spatial relationship of the previously implanted inferior vena cava TricValve prosthesis with the right atrium (RA) anticipating possible interactions with the transcatheter tricuspid valve replacement delivery system (E), including measurement of prosthetic extension into the RA (F). AP = antero-posterior; TV = tricuspid valve. Preprocedural Computed Tomography Planning for Transcatheter Tricuspid Valve Replacement Computed tomography reconstruction of the tricuspid annulus in diastole (A) and systole (B), demonstrating annular dimensions, perimeter, and area measurements used for device sizing. Computed tomography-based assessment of right ventricle septo-lateral dimensions in diastole (C) and systole (D). Spatial relationship of the previously implanted inferior vena cava TricValve prosthesis with the right atrium (RA) anticipating possible interactions with the transcatheter tricuspid valve replacement delivery system (E), including measurement of prosthetic extension into the RA (F). AP = antero-posterior; TV = tricuspid valve. The procedure was performed under general anesthesia with combined fluoroscopic and TEE guidance. Given the presence of a mechanical MV prosthesis, which could have limited echocardiographic visualization because of acoustic shadowing,1 3-dimensional intracardiac echocardiography (VeriSight Pro, Philips) was used as a complementary tool in case TEE imaging proved to be suboptimal. Ultrasound-guided right femoral venous access was obtained and preclosed with 2 ProStyles (Abbott). A steerable 8.5-F catheter (Agilis, Abbott) was advanced into the RA, and a Safari guidewire was positioned at the RV apex (Figure 3A). Valve advancement through the previously implanted TricValve occurred uneventfully without any friction and/or difficulty (Figure 3B, Video 4). Valve deployment was then safely and performed in a stepwise fashion according to the standard procedural protocol (Figures 3C and 3D, Video 5, Video 6, Video 7). Following repeated echocardiographic confirmation of correct native leaflet engagement and appropriate positioning of all anchoring elements, the valve was fully released (Figures 3E and 3F, Video 8). No significant interference with the IVC prosthesis was observed throughout the procedure.Figure 3Evoque ImplantationPositioning of the Safari guidewire in the right ventricle apex across the tricuspid valve through a steerable catheter after right femoral venous access (A). Advancement of the Evoque delivery system across the previously implanted inferior vena cava TricValve prosthesis without significant interaction or resistance and tricuspid valve crossing (B). Stepwise deployment of the Evoque valve (C and D). Final valve release after confirmation of correct native leaflet engagement, appropriate positioning of the anchoring elements, and absence of significant interference with the previously implanted caval prostheses (E and F). Final transesophageal echocardiography demonstrating a well-functioning Evoque prosthesis with no paravalvular leak and only trace residual central tricuspid regurgitation (G). Continuous-wave Doppler assessment showing normal postprocedural transvalvular gradients (H). ICE = intracardiac echocardiography; LA = left atrium; MV = mitral valve; VTI = velocity time integral; other abbreviations as in Figure 1. Evoque Implantation Positioning of the Safari guidewire in the right ventricle apex across the tricuspid valve through a steerable catheter after right femoral venous access (A). Advancement of the Evoque delivery system across the previously implanted inferior vena cava TricValve prosthesis without significant interaction or resistance and tricuspid valve crossing (B). Stepwise deployment of the Evoque valve (C and D). Final valve release after confirmation of correct native leaflet engagement, appropriate positioning of the anchoring elements, and absence of significant interference with the previously implanted caval prostheses (E and F). Final transesophageal echocardiography demonstrating a well-functioning Evoque prosthesis with no paravalvular leak and only trace residual central tricuspid regurgitation (G). Continuous-wave Doppler assessment showing normal postprocedural transvalvular gradients (H). ICE = intracardiac echocardiography; LA = left atrium; MV = mitral valve; VTI = velocity time integral; other abbreviations as in Figure 1. Final TEE and intracardiac echocardiography revealed no paravalvular leak and only trace central regurgitation, with normal transvalvular gradients (Figures 3G and 3H, Video 9); the previously implanted TricValve showed prosthetic leaflets frozen in an open position and no residual regurgitation (Video 10). Outcome and Follow-Up A few days after the procedure, implantation of a leadless pacemaker (Micra, Medtronic) was required because of significant bradycardia. The patient was discharged 5 days later in stable clinical condition. Predischarge transthoracic echocardiography confirmed intraprocedural findings, with a mean transvalvular gradient of 2-3 mm Hg. At 1-month follow-up, the patient demonstrated improvement in dyspnea and signs of right-sided heart failure, with reduced lower-limb edema and diuretic dosage requirements. Discussion Heterotopic caval valve implantation with the TricValve system has been proposed as a compassionate strategy to alleviate venous congestion in patients with torrential TR who are not suitable for transcatheter repair. Early clinical experience demonstrated meaningful symptomatic improvement through mitigation of caval backflow.2,3 However, by leaving the native tricuspid valve untreated, this approach does not address the underlying valvular pathology. Experience with heterotopic caval valve implantation remains limited, and systematic long-term follow-up data are lacking. Prosthetic dysfunction after heterotopic caval valve implantation has so far been reported only in isolated cases, and the present report represents one of the earliest descriptions of cusp prolapse leading to severe regurgitation at the level of the IVC prosthesis. As with other treatments for the tricuspid valve, TR recurrence can occur over time and, when associated with symptomatic recurrence, it may require further intervention.4 The interval between TricValve implantation and prosthetic dysfunction, characterized by loss of coaptation and prolapse of the valve cusps, was relatively short in this case. Although the exact mechanism cannot be definitively established, the markedly elevated RA pressure may have contributed to early degeneration of the IVC prosthesis by increasing hemodynamic loading and repetitive mechanical stress on the prosthetic leaflets. These considerations highlight the need for careful follow-up after caval valve implantation. At present, the management of symptomatic prosthesis failure following TricValve implantation remains largely undefined, and no standardized interventional strategy has been established. As medical therapy is often ineffective in relieving symptoms and surgical risk remains prohibitive in most of these patients, TTVR emerges as a promising therapeutic option, offering a definitive solution by tackling the primary pathophysiological mechanism of right-sided heart failure. This may be particularly relevant for patients previously treated with TricValve before the availability of dedicated orthotopic TTVR platforms who subsequently develop prosthetic valve degeneration. To our knowledge, this represents the first reported case of Evoque TTVR performed in a patient with previously implanted caval valves. This scenario inherently raises important anatomical and procedural considerations, including potential device–device interaction, reduced RA working space, as well as interference with valve advancement or anchoring, and altered intracardiac flow dynamics. In this case, comprehensive multimodality imaging played a central role in procedural planning. Cardiac CT enabled precise assessment of the spatial relationship between the TricValve prosthesis and the native tricuspid annulus, confirming sufficient space to safely accommodate the Evoque delivery system and valve without compromising expansion, stability, or anchoring. From a procedural perspective, advancement of the delivery system across the previously implanted IVC prosthesis was achieved smoothly, without friction or instability, and no interaction between the 2 devices was observed during deployment. Importantly, final echocardiographic assessment demonstrated not only optimal Evoque positioning with complete abolition of TR but also functional unloading of the heterotopic prosthesis, whose leaflets appeared fixed in an open position and free of residual regurgitation. Overall, this case provides several clinically relevant insights by demonstrating the feasibility and safety of TTVR with the Evoque platform after failed heterotopic caval valve implantation. It also underscores the pivotal role of advanced imaging in procedural planning and execution when multiple transcatheter devices coexist. Finally, this case further supports the versatility of Evoque TTVR, demonstrating its ability to effectively address residual severe TR after previous failed transcatheter strategies.5, 6, 7 Conclusions TTVR with the Evoque system was feasible and safe in a patient presenting with structural failure of a prior heterotopic IVC valve. This case supports TTVR as a potential bailout strategy after failed TricValve therapy. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.